The Bulletin
The Times


.

Alebund's AP301 NDA Accepted for Review by China's NMPA

  • Written by PR Newswire

SHANGHAI, Aug. 7, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the New Drug Application (NDA) for AP301 capsules, a novel oral iron-based phosphate binder, for the treatment of hyperphosphatemia in patients with chronic...

The Bulletin Magazine

Practical Guide to Roller Shutters for Safer, More Comfortable Homes

Why the Advertised Rate on a Bonus Saver Account Isn't What Most Savers Actually Earn

The Essential Bathroom Renovation Supplies Checklist Before You Start

Pull Up Stands: A Convenient Display Option for Events and Promotions

How Mining Hose Selection Can Improve Material Transfer Systems

Electric Sliding Door: What to Consider Before Choosing One

What Is Included in a Professional Roof Repair Service on the Gold Coast?

The Unglamorous Baby Buys That Save Australian Parents the Most Time

Cryptocurrency Trading in 2026_ Why Regulated Education Is the New Standard

How Mining Hose Routing Can Influence Wear and Transfer Efficiency

Cryotherapy in Melbourne: What Skin Lesions Can Be Treated with Targeted Cold Therapy?

10 Restaurants in Cranbourne You Need to Try Before 2027

hacklink hack forum hacklink film izle hacklink PadişahbetGalabetholiganbetholiganbetholiganbetcasinos not on gamstopnon uk casinosnot on gamstopcasinos not on gamstopcasinos non gamblock ukiptviptv satın alzlibraryzlibraryz-libraryjojobet girişdeneme bonusuPadişahbetVipparkPadişahbetdeneme bonusujojobet girişPadişahbetcanlı maç izleSahabet girişjojobetjojobetjojobetviljo kasinot kirjautuminenGalabetzimpler kasinotGalabet1xbetjojobetjojobet